Table 1.

Clinical features of MDS patients.

Sample	Sex	Age	WHO subtype	Blasts of BM (%)	Hb (g/l)	PLT (×109/l)	ANC (×109/l)	Cytogenetics	IPSS-R
01	Male	56	MDS-EB-1	9	63	24	1.3	(–)	5.5
02	Male	74	MDS-EB-2	15.5	70	155	0.51	(–)	6
03	Female	63	MDS-EB-1	8	42	34	2.23	(–)	5.5
04	Female	63	MDS-EB-2	19	74	37	0.59	5q−, 20q−	7
05	Male	54	MDS−U	1	48	83	0.82	(–)	3
06	Female	33	MDS-SLD	4	117	137	2.32	(–)	2
07	Female	83	MDS-SLD	1	79	114	1.64	5q−	2.5
08	Male	47	MDS-MLD	0	66	15	0.41	(–)	3
09	Female	64	MDS-SLD	0	87	219	2.21	(–)	2
10	Male	59	MDS-MLD	0	112	50	0.41	(–)	2
11	Female	43	MDS-MLD	0	56	34	1.72	(–)	3.5
12	Female	57	MDS-SLD	2.5	58	165	1.24	(–)	3.5
13	Male	49	MDS-SLD	0	110	44	1.47	(–)	2
14	Male	63	MDS-EB-2	12	50	3	0.26	(–)	7
15	Female	65	MDS-EB-2	19	80	89	0.3	(–)	6
16	Male	71	MDS-RS-MLD	3	91	80	1.17	7q−	4.5
17	Male	74	MDS-U	1	61	78	1.33	20q−, +8	4
18	Female	42	MDS-EB-2	16.5	67	6	0.7	−7	9
19	Female	73	MDS-EB-1	8	102	295	0.37	(–)	3.5
20	Female	57	MDS-EB-1	5.5	112	35	1.05	(–)	3
21	Male	40	MDS-MLD	2	72	63	2.41	(–)	3
22	Male	39	MDS-EB-1	9	64	139	1.46	(–)	3.5
23	Male	40	MDS-MLD	1	89	35	1.39	(–)	3
24	Male	71	MDS-U	1	138	61	4.07	5q−, +8, −Y	3.5
25	Male	69	MDS-SLD	0.5	126	333	0.84	7q−, 20q−	3
26	Male	67	MDS-EB2	13.5	86	17	0.47	+8	7.5
27	Male	61	MDS-EB2	18.5	78	34	10.35	20q−	6.5
28	Male	62	MDS-EB2	15	66	112	0.19	(–)	6
29	Male	30	MDS-SLD	0.5	66	14	5.63	7q−	4.5
30	Male	78	MDS-U	4.5	88	52	0.88	(–)	3.5
31	Male	72	MDS-RS-MLD	0	104	21	2.18	7q−	3
32	Male	62	MDS-EB-2	18.5	75	30	11.03	20q−	6.5
33	Male	74	MDS-EB-2	10.5	95	42	2.6	(–)	6
34	Male	59	MDS-EB-1	5	87	213	4.47	5q−; −7	6
35	Male	71	MDS-MLD	1	118	76	3.79	(–)	1.5
36	Female	67	MDS-EB-1	6.5	60	23	1.1	(–)	5.5
37	Female	42	MDS-MLD	0	64	39	0.69	20q−	4
38	Female	60	MDS-MLD	0	65	53	1.44	(–)	3
39	Female	66	MDS-EB-2	18.5	81	44	6.66	(–)	6

MDS: myelodysplastic syndromes; BM: bone marrow; Hb: haemoglobin; PLT: platelet; ANC: absolute neutrophil count.